Navigation Links
Amira Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
Date:1/11/2010

SAN DIEGO, Jan. 11 /PRNewswire/ -- Amira Pharmaceuticals, Inc., a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease, announced today that Robert Baltera, Chief Executive Officer, will present a company overview at the 28th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for 2:00 p.m. PST on Thursday, January 14, at the Westin St. Francis in San Francisco, Calif. The J.P. Morgan Healthcare Conference is one of the largest and most informative healthcare investment symposiums in the industry. Over 300 public and private companies are expected to present at the conference.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair®. The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future. For more information, visit

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist
2. Amira Pharmaceuticals Hires Industry Veteran for CFO Position
3. China Yongxin Pharmaceuticals Opened Three New Stores in 2009 and Expanded Customer Base
4. China Yongxin Pharmaceuticals Projects Higher Net Income and EPS on Reduced Revenue for Full-Year 2009
5. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
6. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
7. Poniard Pharmaceuticals Announces $6.5 Million Financing
8. Titan Pharmaceuticals to Receive $3 Million Loan
9. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
10. Lotus Pharmaceuticals, Inc. Appoints OTC Division Head
11. Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 Research and Markets ( ... "Israel Biomedical Sensors Market - Growth, Trends & Forecasts ... The Israel Biomedical Sensors market is estimated at $0.19 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
(Date:8/31/2015)... 31, 2015  US-Australian drug discovery company, Novogen ... confirmed its comprehensive scientific review has identified high ... areas of unmet patient need. Novogen is moving ... projects prior to entering into Phase 1 clinical ... Acting Chief Executive Officer, Iain Ross , ...
(Date:8/31/2015)... ... August 31, 2015 , ... Regulatory agencies have acknowledged impurities ... approval process. Thus, innovator companies must understand what will be needed in the ... has been hosting multiple educational panels and seminars for experts to share advice ...
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Global & USA BioSimilar ... The highly awaited US Biosimilar market will ... awaited filigrastim biologic, Zarxio. How will the global market ... author reveals that biosimilars could save the US economy ...
Breaking Biology Technology:Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3Global & USA BioSimilar Market Analysis Report 2015-2021 2Global & USA BioSimilar Market Analysis Report 2015-2021 3
... March 6, the Air Force Office of Scientific Research ... Mirkin from Northwestern University. Professor Mirkin is a ... for his development of nanoparticle-based biodetection schemes, the invention ... his contributions to supramolecular chemistry, nanoelectronics, and nanooptics. He ...
... WOODLANDS, Texas, March 20, 2012   Lexicon Pharmaceuticals, ... that the U.S. Food and Drug Administration (FDA) has ... telotristat etiprate (LX1032) for the treatment of carcinoid ... neuroendocrine tumors that usually originate from the gastrointestinal tract ...
... March 20, 2012  Watson Pharmaceuticals, Inc. (NYSE: ... Inc. has received approval from the United States Food ... (ANDA) for Ibandronate 150mg tablets, the generic equivalent to ... product in the second quarter. BONIVA® 150mg tablets had ...
Cached Biology Technology:Air Force Office of Scientific Research hosts nanotechnology pioneer 2Air Force Office of Scientific Research hosts nanotechnology pioneer 3Air Force Office of Scientific Research hosts nanotechnology pioneer 4FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome 2FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome 3FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome 4Watson's Generic BONIVA® 150mg Receives FDA Approval 2
(Date:8/31/2015)... Canada , August 31, 2015 ... of biometrics technology in government digitization projects to drive ... to a recently published TechSci Research report, " India Biometrics ... India is projected to grow at a ... the market is anticipated on account of extensive use of ...
(Date:8/24/2015)... 24, 2015 The consulting company Frost ... biometrics manufacturer DERMALOG and its customized solutions and products for ... Company of the Year Award". DERMALOG is particularly successful with ...   -Cross reference: Picture is available at AP ... On Thursday evening, in South Africa,s ...
(Date:8/19/2015)... HAUPPAUGE, N.Y. , Aug. 19, 2015 /PRNewswire/ ... announced that it has entered into a Definitive ... intellectual property, of iris authentication market leader EyeLock ... transaction, VOXX will have a controlling interest in ... is subject to completion of due diligence.  Expanding ...
Breaking Biology News(10 mins):India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5
... triggered changes in the type of sperm a male produces, ... The study, published in the Proceedings of the National ... for reproduction influences the sperm of many species of African ... strict monogamy to species where females mate with many males ...
... (Jan. 21, 2009) Finding cures for hearing loss, ... identify people at risk for tuberculosis are goals of ... L.E. Simmons Family Foundation Collaborative Research Fund. The fund, ... diagnose and treat diseases, supports collaboration among researchers at ...
... This month, the City of Newark, Delaware became the ... car to store and provide power for the local ... electricity alone, is specifically designed to store energy and ... the concept, called Vehicle-to-Grid (V2G). With the City of ...
Cached Biology News:The more promiscuous the female, the speedier the sperm 2Texas Medical Center researchers win collaborative grants 2Texas Medical Center researchers win collaborative grants 3Texas Medical Center researchers win collaborative grants 4City of Newark first in nation using cars to power grid 2
... for rapid, convenient, and efficient native protein ... utilizes a spin column to make handling ... of proteins which were electro-eluted in their ... exchangers, offering high binding capacity fo all ...
... Disposable. Virgin, optically clear polystyrene ... and alphanumeric coordinates for cell counting. ... number is a new product number, ... number. If showing no availability yet, ...
... The Corning CellBIND surface is produced by ... more hydrophilic surface giving more consistent, even ... CellBIND enhances cell attachment and growth uunder ... medium. • CellBIND may provide a more ...
... suspension array system, 100-240 V, uses xMAP ... to 100 proteins and peptides in one ... of up to 100 color-coded bead sets, ... a unique reactant (enzyme substrates, receptors, antigens, ...
Biology Products: